Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (GB:0Q1G)
LSE:0Q1G
Eli Lilly & Co (0Q1G) Share Price & Analysis
6 Followers
0Q1G Stock Chart & Stats
Day’s RangeCHF0 - CHF0
52-Week RangeCHF244.96 - CHF540.00
Previous CloseCHF540
Volume0.00
Average Volume (3M)N/A
Market Cap
CHF634.11B
Enterprise ValueCHF654.50B
Total Cash (Recent Filing)$2.93B
Total Debt (Recent Filing)$25.23B
Price to Earnings (P/E)12.8
Beta0.18
Next Earnings
Apr 30, 2024EPS Estimate
CHF2.26Last Dividend Ex-Date
Feb 14, 2024Dividend Yield0.65%
Share Statistics
EPS (TTM)5.12
Shares Outstanding950,164,452
10 Day Avg. Volume55
30 Day Avg. VolumeN/A
Standard Deviation0.06
R-Squared0.01
Alpha0.00982
Financial Highlights & Ratios
Price to Book (P/B)-642.32
Price to Sales (P/S)2.36
Price to Cash Flow (P/CF)-553.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue19.18
Enterprise Value/Gross Profit24.20
Enterprise Value/Ebitda82.24
Forecast
1Y Price Target
CHF769.86Price Target Upside42.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Eli Lilly & Co News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessLilly's recent success in the SURMOUNT-OSA clinical trial demonstrates the drug's effectiveness in treating sleep apnea in both PAP and non-PAP patients, signaling a potential expansion in treatment options and market share.
Market ExpansionWith the positive data from the SURMOUNT-OSA trial, Eli Lilly is poised to capture a larger segment of the market for sleep apnea treatments, especially among patients who cannot tolerate current options like CPAP.
Pipeline DevelopmentEli Lilly's strategic focus on its pipeline is yielding promising results, with the anticipated submission of the Alzheimer's drug donanemab, enhancing the company's growth prospects and innovation credibility.
Bears Say
Clinical Trial ConcernsCPAP seemed to underperform at 6% mean AHI reduction from baseline, raising questions about this effect.
Regulatory ChallengesConcerns regarding patient access to medication due to the CTLT/NVO deal could signal regulatory challenges ahead.
Supply IssuesMounjaro and Zepbound TRx trends have recently declined due to supply constraints.
---
Options Prices
Currently, No data available
---
Ownership Overview
11.10% Insiders
24.64% Mutual Funds
26.86% Other Institutional Investors
37.40% Public Companies and
Individual Investors
0Q1G FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest share price was CHF244.96 and its highest was CHF540.00 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Currently, no data Available
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Apr 30, 2024 which is in 4 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Feb 06, 2024. The company reported CHF2.267 earnings per share for the quarter, beating the consensus estimate of CHF2.091 by CHF0.177.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of CHF1.18 which represents an annual dividend yield of 0.65%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is CHF2.26.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 950,766,100 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of CHF2.267 in its last earnings report, beating expectations of CHF2.091. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Among the largest hedge funds holding Eli Lilly & Co’s share is PRIMECAP Management Co. It holds Eli Lilly & Co’s shares valued at 13B.
---
Eli Lilly & Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF769.86 (42.57% Upside)
CHF769.86 (42.57% Upside)
Blogger Sentiment
Bullish
GB:0Q1G Sentiment 80%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $465.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 57%
Bearish news 43%
Bearish news 43%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.42%
12-Months-Change
Fundamentals
Return on Equity
48.93%
Trailing 12-Months
Asset Growth
29.33%
Trailing 12-Months
Company Description
Eli Lilly & Co
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
---
0Q1G Company Deck
---
0Q1G Earnings Call
Q4 2024
0:00 / 0:00
---
0Q1G Revenue Breakdown
84.44% Net product revenue
15.56% Collaboration and other revenue
---
0Q1G Stock 12 Months Forecast
Average Price Target
CHF769.86
▲(42.57% Upside)
Technical Analysis
Best Analysts Covering 0Q1G
1 Year
1 Year Success Rate
28/29 ratings generated profit
1 Year Average Return
+43.38%
reiterated a buy rating last month
Copying Chris Schott's trades and holding each position for 1 Year would result in 96.55% of your transactions generating a profit, with an average return of +43.38% per trade.
---